drugset
drugset / Trial / NCT03622216

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

NCT03622216 ↗

Phase 2 Completed 46 enrolled Attenua, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough

Timeline

Start
2018-11-05
Primary completion
2019-05-07
Completion
2019-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Bradanicline Small molecule — Oral

Indications

respiratory system disorder